Pfizer vs Takeda Pharmaceutical
PFE and TAK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PFE and TAK compare
Pfizer grew revenue faster over the last twelve months (−0.21% versus −1.7% for Takeda Pharmaceutical).
Pfizer keeps more of each dollar of sales as profit, with a net margin of 6.8% compared with −3.4% at Takeda Pharmaceutical.
Pfizer pays a dividend yielding 5.7%; Takeda Pharmaceutical does not pay one.
Pfizer scores higher on the StockData Score (11 against 5 for Takeda Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PFE | TAK |
|---|---|---|
| Size and price | ||
| Market cap | $171B | – |
| Share price | $29.95 | $20.91 |
| Change, 1 year | 22.2% | 51.9% |
| Change, 5 years | −38.4% | 46.7% |
| Beta (5Y) | 0.44 | 0.22 |
| Employees | 75K | 47K |
| StockData Score | ||
| Total score | 11 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 2 | 2 |
| Health score | 2 | 3 (better) |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 39.4× | – |
| P/S | 2.7× | – |
| P/B | 2.0× | – |
| EV/EBITDA | 16.7× | – |
| P/FCF | 15.5× | – |
| FCF yield | 6.4% | – |
| Fair value | $19.52 | – |
| Margin of safety | −53.4% | – |
| Growth | ||
| Revenue growth (TTM) | −0.21% (better) | −1.7% |
| Revenue growth, 5Y average | 8.5% (better) | 7.1% |
| Net income growth (TTM) | −59.7% (better) | −241% |
| EPS growth (TTM) | −59.6% (better) | −244% |
| EPS growth, 5Y average | −3.6% | – |
| Profitability | ||
| Gross margin | 73.2% (better) | 65.1% |
| Operating margin | – | 0.14% |
| Net margin | 6.8% (better) | −3.4% |
| FCF margin | 17.2% | 19.2% (better) |
| Return on equity | 5.0% (better) | −2.1% |
| Return on invested capital | – | 0.04% |
| Financial health | ||
| Debt / equity | 0.74 | 0.66 (better) |
| Net debt / EBITDA | 4.07 (better) | 5.89 |
| Interest coverage | – | 0.0× |
| Current ratio | 1.27 (better) | 1.09 |
| Altman Z-score | 2.03 | – |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 5.7% | – |
| Years of dividend growth | 15 | – |
| Dividend growth, 5Y average | 2.4% | – |
| Shareholder yield | 5.7% | – |
| Ownership | ||
| Held by institutions | 67.2% | 6.0% |
| Held by insiders | 0.03% | 0.22% |
| Insider net buying, 12 months | $2.8M (better) | −$13.1M |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 2.6% | – |
Go deeper
- PFE stock overview
- PFE income statement
- PFE valuation and score
- TAK stock overview
- TAK income statement
- TAK valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.